[1]
|
Parkin D.M., Bray, F.I. and Devesa, S.S. (2001) Cancer Burden in the Year 2000: the Global Picture. European Journal of Cancer, 37, S4e66. http://dx.doi.org/10.1016/s0959-8049(01)00267-2
|
[2]
|
Bunyaviroch, T. and Coleman, R.E. (2006) PET Evaluation of Lung Cancer. Journal of Nuclear Medicine, 47, 451-469.
|
[3]
|
Bruzzi, J.F. and Munden, R.F. (2006) PET/CT Imaging of Lung Cancer. Journal of Thoracic Imaging, 21, 123-136. http://dx.doi.org/10.1097/00005382-200605000-00004
|
[4]
|
Steinert, H.C. (2010) PET and PET-CT of Lung Cancer. Methods in Molecular Biology, 727, 33-51. http://dx.doi.org/10.1007/978-1-61779-062-1_3
|
[5]
|
Reed, C.E., Harpole, D.H., Posther, K.E., et al. (2003) American College of Surgeons Oncology Group Z0050 Trial. Results of the American College of Surgeons Oncology Group Z0050 Trial: The Utility of Positron Emission Tomography in Staging Potentially Operable Non-Small Cell Lung Cancer. The Journal of Thoracic and Cardiovascular Surgery, 126, 1943-1951. http://dx.doi.org/10.1016/j.jtcvs.2003.07.030
|
[6]
|
Stroobants, S.G., D’Hoore, I., Dooms, C., et al. (2003) Additional Value of Wholebody Fluorodeoxyglucose Positron Emission Tomography in the Detection of Distant Metastases of Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 4, 242-247. http://dx.doi.org/10.3816/CLC.2003.n.005
|
[7]
|
Maziak, D.E., Darling, G.E., Inculet, R.I., Gulenchyn, K.Y., et al. (2009) The Impact of Positron Emission Tomography (PET) Imaging in Staging Potentially Surgically Resectable Non-Small Cell Lung Cancers: A Prospective, Multicenter Randomized Clinical Trial ELPET. Annals of Internal Medicine, 151, 221-228. http://dx.doi.org/10.7326/0003-4819-151-4-200908180-00132
|
[8]
|
Skoura, E., Datseris, I.E., Platis, I., et al. (2012) Role of Positron Emission Tomography in the Early Prediction of Response to Chemotherapy in Patients with Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 13, 181-187. http://dx.doi.org/10.1016/j.cllc.2011.05.004
|
[9]
|
Downey, R.J., Akhurst, T., Gonen, M., et al. (2004) Pre-Operative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival after Lung Cancer Resection. Journal of Clinical Oncology, 22, 3255-3260. http://dx.doi.org/10.1200/JCO.2004.11.109
|
[10]
|
Degirmenci, B., Wilson, D., Laymon, C.M., Becker, C., Mason, N.S., Bencherif, B., Agarwal, A., Luketich, J., Landreneau, R. and Avril, N. (2008) SUV-Based Evaluations of Solitary Pulmonary Nodules Using FDG-PET/CT. Nuclear Medicine Communications, 29, 614-622. http://dx.doi.org/10.1097/MNM.0b013e3282f9b5a0
|
[11]
|
Iskender, I., kadioglu, S., Kosar, A., Atasalihi, A. and Kir, A. (2011) Is There Any Maximum Standardized Uptake Value Variation among Positron Emission Tomography Scanners for Mediastinal Staging in Non-Small Cell Lung Cancer? Interactive Cardiovascular and Thoracic Surgery, 12, 965-969. http://dx.doi.org/10.1510/icvts.2010.258103
|
[12]
|
Paesmans, M., Berghmans, T., Dusart, M., et al. (2010) Primary Tumor Standardized Uptake Value Measured on Fluorodeoxyglucose Positron Emission Tomography Is of Prognostic Value for Survival in Non-Small Cell Lung Cancer: Update of a Systematic Review and Meta-Analysis by the European Lung Cancer. Working Party for the International Association for the Study of Lung Cancer Staging Project. Journal of Thoracic Oncology, 5, 612-619. http://dx.doi.org/10.1097/JTO.0b013e3181d0a4f5
|
[13]
|
Kanstrup, I.L., Klausen, T.L., Bojsen-Moller, J., et al. (2009) Variability and Reproducibility of Hepatic FDG Uptake Measured as SUV as well as Tissue-To-Blood Background Ratio Using Positron Emission Tomography in Healthy Humans. Clinical Physiology and Functional Imaging, 29, 108-113. http://dx.doi.org/10.1111/j.1475-097X.2008.00846.x
|
[14]
|
Kubota, K., Watanabe, H., Murata, Y., et al. (2011) Effects of Blood Glucose Level on FDG Uptake by Liver: A FDG-PET/CT Study. Nuclear Medicine and Biology, 38, 347-351. http://dx.doi.org/10.1016/j.nucmedbio.2010.09.004
|
[15]
|
Boellaard, R., Oyen, W.J., Hoekstra, C.J., et al. (2008) The Netherlands Protocol for Standardisation and Quantification of FDG Whole Body PET Studies in Multi-Centre Trials. European Journal of Nuclear Medicine and Molecular Imaging, 35, 2320-2333. http://dx.doi.org/10.1007/s00259-008-0874-2
|
[16]
|
Depierre, A., Milleron, B., Moro-Sibilot, D., Chevret, S., Quoix, E., Lebeau, B., Braun, D., Breton, J.L., Lemarie, E., Gouva, S., Paillot, N., Brechot, J.M., Janicot, H., Lebas, F.X., Terrioux, P., Clavier, J., Foucher, P., Monchatre, M., Coetmeur, D., Level, M.C., Leclerc, P., Blanchon, F., Rodier, J.M., Thiberville, L., Villeneuve, A., Westeel, V., Chastang, C. and French Thoracic Cooperative Group (2002) Preoperative Chemotherapy Followed by Surgery Compared with Primary Surgery in Resectable Stage I (Except T1N0), II, and IIIa Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 20, 247-253. http://dx.doi.org/10.1200/JCO.20.1.247
|
[17]
|
Cerfolio, R.J., Bryant, A.S., Ohja, B. and Bartolucci, A.A. (2005) The Maximum Standardized Uptake Values on Positron Emission Tomography of a Non-Small Cell Lung Cancer Predict Stage, Recurrence, and Survival. The Journal of Thoracic and Cardiovascular Surgery, 130,151-159. http://dx.doi.org/10.1016/j.jtcvs.2004.11.007
|
[18]
|
Okereke, I.C., Gangadharan, S.P., Kent, M.S., Nicotera, S.P., Shen, C. and DeCamp, M.M. (2009) Standard Uptake Value Predicts Survival in Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 88, 911-915. http://dx.doi.org/10.1016/j.athoracsur.2009.05.083
|
[19]
|
Ahuja, V., Coleman, R.E., Herndon, J. and Patz Jr, E.F. (1998) The Prognostic Significance of Fluorodeoxyglucose Positron Emission Tomography Imaging for Patients with Non-Small Cell Lung Carcinoma. Cancer, 83, 918-924. http://dx.doi.org/10.1002/(SICI)1097-0142(19980901)83:5<918::AID-CNCR17>3.0.CO;2-Y
|
[20]
|
Vansteenkiste, J.F., Stroobants, S.G., De Leyn, P.R., Verbeken, E.K., Deneffe, G.J., Mortelmans, L.A. and Demedts, M.G. (1999) Prognostic Importance of the Standardized Uptake Value on 18F-Fluoro-2-deoxy-glucose-positron emission Tomography Scan in Non-Small Cell Lung Cancer: An Analysis of 125 Cases. Journal of Clinical Oncology, 17, 3201-3206.
|
[21]
|
Dhital, K., Saunders, C.A., Seed, P.T., O’Doherty, M.J. and Dussek, J. (2000) 18Fluorodeoxyglucose Positron Emission Tomography and Its Prognostic Value in Lung Cancer. European Journal Cardio-Thoracic Surgery, 18, 425-428. http://dx.doi.org/10.1016/S1010-7940(00)00535-2
|
[22]
|
Hicks, R.J., Kalff, V., MacManus, M.P., Ware, R.E., Hogg, A., McKenzie, A.F., Matthews, J.P. and Ball, D.L. (2001) 18F-FDG PET Provides High-Impact and Powerful Prognostic Stratification in Staging Newly Diagnosed Non-Small Cell Lung Cancer. Journal of Nuclear Medicine, 42, 1596-1604.
|
[23]
|
Higashi, K., Ueda, Y., Arisaka, Y., Sakuma, T., Nambu, Y., Oguchi, M., Seki, H., Tonami, H. and Yamamoto, I. (2002) 18F-FDG Uptake as a Biologic Prognostic Factor for Recurrence in Patients with Surgically Resected Non-Small Cell Lung Cancer. Journal of Nuclear Medicine, 43, 39-45.
|
[24]
|
Jeong, H.J., Min, J.J., Park, J.M., Chung, J.K., Kim, B.T., Jeong, J.M., Lee, D.S., Lee, M.C., Han, S.K. and Shim, Y.S. (2002) Determination of the Prognostic Value of 18F-Fluorodeoxyglucose Uptake by Using Positron Emission Tomography in Patients with Non-Small Cell Lung Cancer. Nuclear Medicine Communications, 23, 865-870. http://dx.doi.org/10.1097/00006231-200209000-00010
|
[25]
|
Borst, G.R., Belderbos, J.S., Boellaard, R., Comans, E.F., De-Jaeger, K., Lammertsma, A.A. and Lebesque, J.V. (2005) Standardised FDG Uptake: A Prognostic Factor for Inoperable Non-Small Cell Lung Cancer. European Journal of Cancer, 41, 1533-1541. http://dx.doi.org/10.1016/j.ejca.2005.03.026
|
[26]
|
Eschmann, S.M., Friedel, G., Paulsen, F., Reimold, M., Hehr, T., Budach, W., Scheiderbauer, J., Machulla, H.J., Dittmann, H., Vonthein, R. and Bares, R. (2006) Is Standardised 18F-FDG Uptake Value an Outcome Predictor in Patients with Stage III Non-Small Cell Lung Cancer? European Journal of Nuclear Medicine and Molecular Imaging, 33, 263-269. http://dx.doi.org/10.1007/s00259-005-1953-2
|
[27]
|
Kramer, H., Post, W.J., Pruim, J. and Groen, H.J.M. (2006) The Prognostic Value of Positron Emission Tomography in Non-Small Cell Lung Cancer: Analysis of 266 Cases. Lung Cancer, 52, 219-224. http://dx.doi.org/10.1016/j.lungcan.2005.12.011
|
[28]
|
Um, S.W., Kim, H., Koh, W.J., Suh, G.Y., Chung, M.P., Kwon, O.J., Choi, J.Y., Han, J., Lee, K.S. and Kim, J. (2009) Prognostic Value of 18F-FDG Uptake on Positron Emission Tomography in Patients with Pathologic Stage I Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 4, 1331-1336. http://dx.doi.org/10.1097/JTO.0b013e3181b6be3e
|
[29]
|
Uehara, H., Tsutani, Y., Okumura, S., Nakayama, H., Adachi, S., Yoshimora, M., Miyata, Y. and Okada, M. (2013) Prognostic Role of Positron Emission Tomography and High-Resolution Computed Tomography in Clinical Stage IA Lung Adenocarcinoma. Annals of Thoracic Surgery, 96, 1958-1965. http://dx.doi.org/10.1016/j.athoracsur.2013.06.086
|
[30]
|
Hanin, F.X., Loneux, M., Cornet, J., Noirhomme, P., Coulon, C., Distexhe, J. and Poncelet, A.J. (2008) Prognostic Value of FDG Uptake in Early Stage Non-Small Cell Lung Cancer. Journal of Cardiothoracic Surgery, 33, 819-823. http://dx.doi.org/10.1016/j.ejcts.2008.02.005
|
[31]
|
Nair, V.S., Krupitskaya, Y. and Gould, M.K. (2009) Positron Emission Tomography 18F-Flourodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated Stage I Non-Small Cell Lung Cancer: A Systematic Review. Journal of Thoracic Oncology, 4, 1473-1479. http://dx.doi.org/10.1097/JTO.0b013e3181bccbc6
|